StockData
Celldex Therapeutics, Inc. logo

Celldex Therapeutics, Inc. (CLDX) stock

CLDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$27.55−0.49 (-1.75%)

Close on Nov 18, 2026Market cap $2.16BP/E –Yield –

Celldex Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Celldex Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$325.83M. For fiscal 2025 it was -$287.37M. The highest annual figure on record is -$6.46M in fiscal 2010.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$287.37M–
FY2024Dec 31, 2024-$195.08M–
FY2023Dec 31, 2023-$154.54M–
FY2022Dec 31, 2022-$115.23M–
FY2021Dec 31, 2021-$71.24M–
FY2020Dec 31, 2020-$63.35M–
FY2019Dec 31, 2019-$55.03M–
FY2018Dec 31, 2018-$156.44M–
FY2017Dec 31, 2017-$121.53M–
FY2016Dec 31, 2016-$132.92M–
FY2015Dec 31, 2015-$129.54M–
FY2014Dec 31, 2014-$122.43M–
FY2013Dec 31, 2013-$81.44M–
FY2012Dec 31, 2012-$58.08M–
FY2011Dec 31, 2011-$43.40M–
FY2010Dec 31, 2010-$6.46M–
FY2009Dec 31, 2009-$36.85M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$80.62M–
Q1 FY2026Mar 31, 2026-$84.44M–
Q4 FY2025Dec 31, 2025-$87.15M–
Q3 FY2025Sep 30, 2025-$73.62M–
Q2 FY2025Jun 30, 2025-$63.86M–
Q1 FY2025Mar 31, 2025-$62.74M–
Q4 FY2024Dec 31, 2024-$56.03M–
Q3 FY2024Sep 30, 2024-$52.13M–
Q2 FY2024Jun 30, 2024-$46.32M–
Q1 FY2024Mar 31, 2024-$40.61M–
Q4 FY2023Dec 31, 2023-$47.63M–
Q3 FY2023Sep 30, 2023-$41.24M–
Q2 FY2023Jun 30, 2023-$33.21M–
Q1 FY2023Mar 31, 2023-$32.47M–
Q4 FY2022Dec 31, 2022-$27.89M–
Q3 FY2022Sep 30, 2022-$27.70M–
Q2 FY2022Jun 30, 2022-$36.40M–
Q1 FY2022Mar 31, 2022-$23.26M–
Q4 FY2021Dec 31, 2021-$20.34M–
Q3 FY2021Sep 30, 2021-$20.82M–
Q2 FY2021Jun 30, 2021-$13.44M–
Q1 FY2021Mar 31, 2021-$16.64M–
Q4 FY2020Dec 31, 2020-$24.78M–
Q3 FY2020Sep 30, 2020-$14.34M–
Q2 FY2020Jun 30, 2020-$11.37M–
Q1 FY2020Mar 31, 2020-$12.87M–
Q4 FY2019Dec 31, 2019-$12.99M–
Q3 FY2019Sep 30, 2019-$11.84M–
Q2 FY2019Jun 30, 2019-$12.26M–
Q1 FY2019Mar 31, 2019-$17.94M–
Q4 FY2018Dec 31, 2018-$12.12M–
Q3 FY2018Sep 30, 2018-$7.76M–
Q2 FY2018Jun 30, 2018-$16.87M–
Q1 FY2018Mar 31, 2018-$119.68M–
Q4 FY2017Dec 31, 2017-$25.53M–
Q3 FY2017Sep 30, 2017-$31.96M–
Q2 FY2017Jun 30, 2017-$28.93M–
Q1 FY2017Mar 31, 2017-$35.11M–
Q4 FY2016Dec 31, 2016-$34.85M–
Q3 FY2016Sep 30, 2016-$29.99M–

More Celldex Therapeutics figures

See a number that looks wrong?